UFP Technologies (UFPT) Q4 2025 earnings review
Growth Decelerates as Acquisitions Lap, but DR Expansion Secures Long-Term Pipeline
UFP Technologies saw its headline growth decelerate sharply in Q4, with revenue up just 3.4% YoY as the company lapped prior-year acquisitions and organic growth remained flat. The bottom line also faced pressure, with Adjusted EPS declining slightly YoY to $2.44. The much-discussed labor disruptions at the AJR facility showed significant improvement—costing $1.2M in Q4 versus $3.0M in Q3—but still compressed gross margins. Despite the near-term optical slowdown, management secured a critical contract extension through 2029 with their largest customer and is aggressively expanding the Dominican Republic footprint, reinforcing the structural pivot toward high-margin MedTech.
🐂 Bull Case
The operational penalty from the E-Verify workforce turnover at AJR dropped from $3M in Q3 to $1.2M in Q4. As efficiency improves, the ~100 bps drag on gross margin will reverse, providing a profitability tailwind in 2026.
Extending the largest customer contract through 2029 and adding multiple new facilities (a 6th in La Romana, a new one in Santiago) locks in a long-term, low-cost manufacturing advantage and guarantees future volume.
🐻 Bear Case
Organic sales were flat in both Q3 and Q4, ending the year at a sluggish 1.5%. Excluding the seven acquisitions completed across 2024 and 2025, the core business lacks near-term topline momentum.
Adjusted operating income declined 9.6% YoY in Q4. Despite labor improvements, higher SG&A (up to 12.4% of sales from 11.2% adjusted) and lapping acquisition comps put the brakes on earnings growth.
⚖️ Verdict: ⚪
Neutral. The optical deceleration in revenue and earnings is stark, but largely expected as M&A contributions lap. The resolution of the AJR labor crisis and massive commitments to the Dominican Republic footprint suggest a stronger setup for 2026, provided organic demand reaccelerates.
Key Themes
AJR Labor Crisis Impact Reversing
The e-Verify-driven workforce turnover at the AJR facility in Illinois, which severely disrupted operations in Q2 and Q3, is finally subsiding. The gross margin hit more than halved sequentially to $1.2M in Q4 (down from $3.0M in Q3). Management expects continued progress until the issue is fully resolved, but it still dragged Q4 gross margins down to 28.2% (from 29.2% a year ago). Absent this penalty, Q4 gross margins would have been a healthy 29.0%.
Dominican Republic Aggressive Expansion
UFP is doubling down on its low-cost manufacturing footprint. In La Romana, the company extended its contract with its largest customer (implied Intuitive Surgical) through 2029, securing volume increases and launching new programs, which requires adding a sixth facility. In Santiago, a new facility planned for Q2 2026 will localize a third major program in the Safe Patient Handling space. This footprint is UFP's primary competitive moat for winning large-scale, long-term MedTech contracts.
Organic Growth Stagnation
For the second consecutive quarter, organic sales growth was essentially flat (~0%), bringing the full-year organic growth rate to an anemic 1.5%. While headline revenue grew 19.5% for the year, almost all of this was driven by acquisitions. With those acquisitions now fully absorbed into the baseline, the lack of organic momentum is glaring and will require the newly launched robotic and patient handling programs to quickly scale in 2026 to offset the stagnation.
Deliberate Pivot to MedTech Continues
The divergence between Medical and Non-Medical segments remains a core theme. MedTech sales grew 4.2% in Q4 (and 23.2% for the year), while Non-Medical sales declined 6.0% in Q4 (and 11.5% for the year). Management is actively de-prioritizing legacy Advanced Components to focus resources on higher-margin, stickier healthcare applications.
Other KPIs
Decelerating. Adjusted operating income fell 9.6% YoY in Q4, down from $26.0 million in the prior year. This reflects the combination of flat organic growth, the $1.2M AJR labor penalty, and elevated SG&A costs (which rose to 12.4% of sales from 11.2% on an adjusted basis) to support recent acquisitions.
Reversing. After strong double-digit growth in the first half of the year, Adjusted EBITDA declined 6.8% YoY in Q4 (from $30.4M). For the full year, however, Adjusted EBITDA grew 12.8% to $121.1M, showcasing the cash-generation power of the integrated assets.
Guidance
Accelerating. Management explicitly called out the Safe Patient Handling space as a substantial market opportunity, projecting significant growth again in 2026. This will be supported by a new facility in Santiago launching in Q2 2026 to ramp up a third major program in this category.
Key Questions
Organic Growth Trajectory
With organic growth sitting at roughly 0% for the past two quarters, what is the embedded organic growth assumption for 2026 as new Dominican Republic facilities come online and destocking headwinds fade?
SG&A Leverage
Adjusted SG&A expenses increased noticeably as a percentage of sales in Q4 to 12.4%. How much of this is structural back-office investment for recent acquisitions versus temporary integration costs?
CapEx Requirements
Can you quantify the expected capital expenditures required in 2026 to build out the sixth facility in La Romana and the new facility in Santiago? How does this impact near-term free cash flow and debt paydown?